Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy
Wang-Bishop L, Wehbe M, Pastora L, Yang J, Kimmel B, Garland K, Becker K, Carson C, Roth E, Gibson-Corley K, Ulkoski D, Krishnamurthy V, Fedorova O, Richmond A, Pyle A, Wilson J. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy. ACS Nano 2024, 18: 11631-11643. PMID: 38652829, PMCID: PMC11080455, DOI: 10.1021/acsnano.3c06225.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsTumor microenvironmentLipid nanoparticlesBreast cancerResponse to ICIResponse to immune checkpoint inhibitorsInfiltration of CD8<sup>+</sup>Models of triple-negative breast cancerCD4<sup>+</sup> T cellsInhibition of tumor growthTriple-negative breast cancerRIG-IIonizable lipid nanoparticlesLung metastatic burdenIncrease tumor immunogenicityBreast tumor microenvironmentSignaling in vitroACTLA-4Immunogenic melanomaCheckpoint inhibitorsTumor immunogenicityImmunotherapeutic modalitiesCancer immunotherapyMetastatic burdenAPD-1Covalent Polymer‐RNA Conjugates for Potent Activation of the RIG‐I Pathway
Palmer C, Pastora L, Kimmel B, Pagendarm H, Kwiatkowski A, Stone P, Arora K, Francini N, Fedorova O, Pyle A, Wilson J. Covalent Polymer‐RNA Conjugates for Potent Activation of the RIG‐I Pathway. Advanced Healthcare Materials 2024, e2303815. PMID: 38648653, PMCID: PMC11493851, DOI: 10.1002/adhm.202303815.Peer-Reviewed Original ResearchChemical design principlesActivation of RIG-I.Retinoic acid-inducible gene ICovalent conjugationRIG-I pathwayNuclease degradationThioether linkageRIG-I.Gene IRNA ligandsElectrostatic interactionsRIG-IDevelopment of therapeuticsPotent activityOligonucleotide therapeuticsNucleaseRNAAnalog carrierNanoparticlesDrug delivery barriersConjugatePolymeric carriersImmunostimulatory activityThioethersIn vivo delivery